A Site-Specific, Sustained-Release Drug Delivery System for Aneurysmal Subarachnoid Hemorrhage.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 26935204)

Published in Neurotherapeutics on April 01, 2016

Authors

Daniel Hänggi1, Nima Etminan2, Hans Jakob Steiger3, Mark Johnson4, M Melissa Peet4, Tom Tice5, Kevin Burton5, Bruce Hudson5, Michele Turner5, Angela Stella6, Parissa Heshmati7, Cara Davis5, Herbert J Faleck8, R Loch Macdonald8,9

Author Affiliations

1: Department of Neurosurgery, University Medical Center Mannheim, Ruprecht-Karls-University Heidelberg, Germany, Mannheim, Germany. daniel.haenggi@medma.uni-heidelberg.de.
2: Department of Neurosurgery, University Medical Center Mannheim, Ruprecht-Karls-University Heidelberg, Germany, Mannheim, Germany.
3: Department of Neurosurgery, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
4: MPI Research, Mattawan, MI, USA.
5: Evonik Industries, Birmingham, AL, USA.
6: Pharmaceutical Associates, LLC, Tampa, FL, USA.
7: Google, Mountain View, CA, USA.
8: Edge Therapeutics, Inc., Berkeley Heights, NJ, USA.
9: Division of Neurosurgery, St. Michael's Hospital, Labatt Family Centre of Excellence in Brain Injury and Trauma Research, Keenan Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Department of Surgery, University of Toronto, Toronto, ON, Canada.

Associated clinical trials:

Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage (NEWTON) | NCT01893190

Articles cited by this

Dose translation from animal to human studies revisited. FASEB J (2007) 15.67

Can animal models of disease reliably inform human studies? PLoS Med (2010) 6.27

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet (1995) 5.11

Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol (2009) 3.66

Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke (2008) 2.90

Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev (2007) 2.08

Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther (2004) 1.96

The efficiency of simulation-based multiple comparisons. Biometrics (1987) 1.91

Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke (2010) 1.78

Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis (2009) 1.70

Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol (2013) 1.64

Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab (2011) 1.58

Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery (2005) 1.56

The efficacy of an abbreviated course of nimodipine in patients with good-grade aneurysmal subarachnoid hemorrhage. J Neurosurg (1999) 1.42

Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs (1989) 1.25

The vascular neural network--a new paradigm in stroke pathophysiology. Nat Rev Neurol (2012) 1.23

Evidence-based cerebral vasospasm management. Neurosurg Focus (2006) 1.09

The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. Arzneimittelforschung (1982) 1.06

Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke (2006) 1.05

Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke (2011) 0.96

Role of p53 and apoptosis in cerebral vasospasm after experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab (2005) 0.94

Ischemia triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine administration or moderate volume expansion/hemodilution in rats. Neurosurgery (2002) 0.92

Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opin Drug Deliv (2005) 0.88

Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care (2010) 0.86

Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J Cereb Blood Flow Metab (2006) 0.86

Reversal of cerebral vasospasm by sphenopalatine ganglion stimulation in a dog model of subarachnoid hemorrhage. Surg Neurol (2005) 0.86

Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery. Neurosurgery (2008) 0.81

In situ forming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm. Eur J Pharm Biopharm (2013) 0.80